Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Digital Health article highlights Bleepa potential

3 Aug 2021 07:00

RNS Number : 2811H
Feedback PLC
03 August 2021
 

RNS REACH

 

Feedback plc

 

Digital Health article highlights potential for Bleepa

 

· Digital Health webinar explores the clinical and regulatory risks of mobile messaging platforms

 

London, 03 August 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, has been featured in an article in Digital Health.

 

The article raises legitimate concerns around security of mobile messaging platforms and discusses the worries of those in the industry wanting to use them. "Mobile messaging systems are a vital tool to enable busy clinicians to manage heavy caseloads, but there is increasing concern about the clinical and regulatory risk to which some systems can expose users and their employers. A recent Digital Health webinar explored this topic and found that more than half of the 130 or so participants were concerned that the messaging platform they used for clinical work did not comply with GDPR. In addition, more than a third of participants were worried that decisions made using their messaging system did not link to their organisation's electronic patient record (EPR)."

 

For the full article, click here: https://www.digitalhealth.net/2021/07/mobile-messaging-platforms-the-clinical-and-regulatory-risks-explored/

 

Dr Tom Oakley, CEO of Feedback, added: "We are delighted to have been featured in Digital Health's article following an extremely insightful webinar which discussed the significant exposure to risk that Trusts and clinicians have when using unregulated devices and the pitfalls that mobile messaging platform must navigate to provide truly secure and safe systems for clinicians to use. We understand that clinicians need a tool that allows them to complete their work in a compliant and secure way. Bleepa is the forerunner in providing exactly these needs and applaud Digital Health's focus on the needs and safety of both clinicians and their patients alike."

 

Tom Oakley joined Digital Health's highly successful webinar alongside Georges Ng Man Kwong, Consultant Chest Physician and Chief Clinical Information Officer at Pennine Acute Hospitals NHS Trust and Darryn Hale, Senior Associate, Beachcroft LLP, a healthcare information governance legal specialist, to discuss 'Safe, secure and compliant clinical messaging: lessons from the COVID-19 pandemic'.

 

For the Digital Health webinar highlights: https://youtu.be/w8NzEHowUUo

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0) 20 3997 7634

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Vivek Bhardwaj

+44 (0)20 3328 5656

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKBBKBBKDAFK
Date   Source Headline
27th Apr 20202:05 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSGrant of Options
20th Apr 20207:00 amRNSBleepa rolled out at PAH NHS Trust for Covid-19
26th Mar 20203:52 pmRNSFeedback Medical to offer Bleepa for COVID-19
18th Feb 20207:00 amRNSInterim Results
3rd Feb 202012:21 pmRNSAppointment of Non-Executive Director
21st Jan 202010:30 amRNSChange of Registered Office
13th Jan 20207:00 amRNSLicence agreement with Imaging Engineering
19th Nov 20197:00 amRNSResult of AGM
18th Nov 20197:01 amRNSAGM Statement
18th Nov 20197:00 amRNSFirst Bleepa pilot study initiated with NHS Trust
24th Oct 20198:28 amRNSFinal Results: Revenue up 23%
17th Oct 20197:00 amRNSUpdate re Bleepa®
27th Sep 20192:52 pmRNSStatement re share price
4th Sep 20197:00 amRNSBleepa - the clinical messaging app - at NHS Expo
3rd Sep 20199:46 amRNSHolding(s) in Company
2nd Sep 201912:24 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSHolding(s) in Company
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSResult of General Meeting
29th Aug 20197:00 amRNSBoard Changes
13th Aug 20192:45 pmRNSPosting of Circular and Notice of General Meeting
12th Aug 20197:00 amRNSProposed placing and subscription to raise £2m
7th Aug 201910:47 amRNSStatement re Online Commentary
26th Jul 201912:03 pmRNSBleepa - revolutionising clinical messaging
10th Jul 20197:00 amRNSOutcome of strategic review and trading update
10th Jun 20199:28 amRNSHolding(s) in Company
7th Jun 201910:07 amRNSHolding(s) in Company
25th Apr 20197:00 amRNSTrading update
9th Apr 20197:00 amRNSFeedback Medical CEO appointed Feedback plc CEO
14th Feb 20197:00 amRNSFeedback Medical appoints Dr Tom Oakley as CEO
24th Jan 20197:00 amRNSHalf-year Results
23rd Jan 20192:02 pmRNSResult of AGM
30th Nov 20185:00 pmRNSTotal Voting Rights
29th Nov 20182:37 pmRNSFinal Results
22nd Nov 201812:59 pmRNSFeedback retains industry standard certification
19th Nov 20182:56 pmRNSDirector/PDMR Shareholding
19th Nov 201811:49 amRNSHolding(s) in Company
16th Nov 20189:16 amRNSHolding(s) in Company
15th Nov 201811:35 amRNSResult of General Meeting
1st Nov 20183:11 pmRNSHolding(s) in Company
31st Oct 20185:00 pmRNSTotal Voting Rights
31st Oct 20184:15 pmRNSHolding(s) in Company
29th Oct 20182:44 pmRNSNotice of General Meeting
25th Oct 20187:00 amRNSProposed placing and subscription to raise £1.375m
22nd Oct 20187:00 amRNSExpansion of European customer base
3rd Oct 20187:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.